New insights into HER2-low breast cancer brain metastasis: A retrospective analysis

New insights into HER2-low breast cancer brain metastasis: A retrospective analysis

Background: A considerable number of patients with breast cancer will suffer from brain metastasis in the advanced setting. The HER2 status serves as a significant prognostic factor and the reference of applying treatment for patients with breast cancer brain metastasis (BCBM). Methods: Between Janu...

Full description

Bibliographic Details
Main Authors:	Hangcheng Xu, Yan Wang, Li Li, Yiqun Han, Yun Wu, Qiang Sa, Binghe Xu, Jiayu Wang
Format:	Article
Language:	English
Published:	Elsevier 2024-02-01
Series:	Breast
Subjects:	HER2-Low Breast cancer Brain metastasis Prognosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977623007956

Similar Items

Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients
by: Yan Wang, et al.
Published: (2024-10-01)

Brain Radiotherapy Combined with Targeted Therapy for HER2-Positive Breast Cancer Patients with Brain Metastases
by: Tang L, et al.
Published: (2024-07-01)

Prognostic value and relapse pattern of HER2‐low in hormone receptor‐positive breast cancer
by: Tong Wei, et al.
Published: (2024-03-01)

Intracranial management of HER-2 overexpression breast cancer with extensive volume or symptomatic brain metastases
by: Juan Li, et al.
Published: (2024-07-01)

Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study
by: Jiayu Wang, et al.
Published: (2024-07-01)

Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study
by: Yun Wu, et al.
Published: (2024-04-01)

Prognostic analysis of the patients with HER2-positive breast cancer adjuvant treated with trastuzumab: a report of 1 246 cases
by: LI Yuefeng, HONG Jin, LI Zhian, RUAN Guodong, CHEN Weiguo
Published: (2023-09-01)

Radiomics signatures for predicting the Ki-67 level and HER-2 status based on bone metastasis from primary breast cancer
by: Hongxiao Zhang, et al.
Published: (2024-01-01)

Efficacy of first‐line dual oral pyrotinib plus capetabine therapy in HER2‐positive metastatic breast cancer: A real‐world retrospective study
by: Shuang Dai, et al.
Published: (2024-06-01)

Histologic heterogeneity predicts patient prognosis of HER2‐positive metastatic breast cancer: A retrospective study based on SEER database
by: Yajie Wang, et al.
Published: (2023-09-01)

NDRG1 is a prognostic biomarker in breast cancer and breast cancer brain metastasis
by: Vaibhavi Joshi, et al.
Published: (2024-03-01)

Unfavorable Prognostic Impact of HER2 2+/FISH-Negativity in Older Patients with HER2-Negative and High-Risk Breast Cancer
by: Wang H, et al.
Published: (2024-11-01)

Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations
by: Shuai Yan, et al.
Published: (2024-09-01)

Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population‐based analysis
by: Hangcheng Xu, et al.
Published: (2022-12-01)

Clinicopathological features and prognosis of patients with HER2-low breast cancer
by: Xin Yang, et al.
Published: (2023-09-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Neratinib for HER2-positive breast cancer with an overlooked option
by: Liting Guo, et al.
Published: (2023-10-01)

Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases
by: Wang C, et al.
Published: (2024-03-01)

Delayed neurotoxicity in HER2-positive breast cancer: a case series on combined SRS and T-DM1 treatment
by: Menekse Turna, et al.
Published: (2024-10-01)

Development and Validation of a Prognostic Nomogram for HR+ HER- Breast Cancer
by: Zhou JY, et al.
Published: (2024-05-01)

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
by: Qian Wu, et al.
Published: (2023-10-01)

Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer
by: Yingying Zhao, et al.
Published: (2024-12-01)

Survival outcomes for HER2-low breast cancer: Danish national data
by: Michael Sode, et al.
Published: (2024-11-01)

HER2 Low Expression in Primary Male Breast Cancer
by: Nobbe K, et al.
Published: (2024-03-01)

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
by: Eurydice Angeli, et al.
Published: (2024-04-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Analysis of factors influencing the efficacy of NAC and prognosis between HER2-zero and HER2-low HR negative breast cancer
by: Jing-Jing Liu, et al.
Published: (2024-11-01)

Study on clinicopathological features and prognosis of HER2 low expression breast cancer
by: RUAN Miao, DA Qian, XU Haimin, DONG Lei, FEI Xiaochun
Published: (2024-10-01)

Editorial: Advances of brain metastasis in breast cancer
by: Wenjie Lv, et al.
Published: (2025-01-01)

Cancer brain metastasis: molecular mechanisms and therapeutic strategies
by: Yu Lu, et al.
Published: (2025-02-01)

Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
by: Chen Y, et al.
Published: (2024-07-01)

Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]
by: Syahruddin FI, et al.
Published: (2024-04-01)

Crosstalk between breast cancer-derived microRNAs and brain microenvironmental cells in breast cancer brain metastasis
by: Munazza S. Khan, et al.
Published: (2024-08-01)

EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
by: Annika Glotzbach, et al.
Published: (2024-05-01)

SLC35A2 expression is associated with HER2 expression in breast cancer
by: Yiran Wang, et al.
Published: (2024-04-01)

Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature
by: Axel de Bernardi, et al.
Published: (2024-01-01)

Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trialResearch in context
by: Shuning Liu, et al.
Published: (2024-11-01)

The prognosis factors among breast cancer patients with extensive axillary lymph node metastasis
by: Jae-Myung Kim, et al.
Published: (2018-06-01)

Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02)
by: Claire Phillips, et al.
Published: (2024-04-01)

Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis
by: Lin-Yu Xia, et al.
Published: (2024-08-01)